ChartRow logo
Data provided bySource: Twelve Data
HALO
$95.97-0.55%
as of close, Nov 17, 2026
☾ AH $95.97 -0.55%
Share this page

HALO — Halozyme Therapeutics Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in HALO be worth today? →
HALO returns: By year · By month · By week · Trailing

Price data

Price
$95.97
YTD price return
+42.60%
YTD total return
+42.60%
Market cap
10.9B
Enterprise value
13.2B
Shares outstanding
114M
52W low
$61.23
52W high
$134.00
From 52W high
-28.38%
From 52W low
+56.74%
52W range
48%$61.23–$134
Beta
0.85

Volume

Rel volume
0.88×
30D volume
2.3M
30D $ vol
268.3M

Insider trading

Insider net 1W
−$6.0M
Insider net 1M
−$6.0M
Insider net 3M
−$21.7M
Insider net 1Y
−$48.6M

Form 4 transactions by trade date, as filed; latest on file 2026-11-16.

Fundamentals

Sales (ttm)
1.8B
Sales/share
$15.81
EPS (ttm)
$3.97
FCF (ttm)
885.9M
FCF/share
$7.77
Book value/share
-$0.48
Net margin
26.93%
ROA
13.98%
Current ratio
3.88

Growth (CAGR, ttm) · 10Y

Sales
+45.06%+32.16%+31.24%+27.41%
Net income
-18.50%+24.11%+3.48%n/a
FCF
+47.10%+35.80%+27.32%n/a
Shares
-3.05%-4.79%-4.13%-1.27%

Per-share growth (CAGR, ttm) · 10Y

EPS
-16.28%+28.67%+7.32%n/a
Sales/share
+49.63%+38.81%+36.90%+29.05%
FCF/share
+51.73%+42.63%+32.81%n/a
Price
+36.04%+33.94%+21.12%+22.14%
Total return
+36.04%+33.94%+21.12%+22.14%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
24.2×
P/OI (ttm)
16.2×
Fwd P/E
9.1×
P/S (ttm)
6.1×
P/B (mrq)
-198.1×
P/FCF (ttm)
12.4×
EV/EBITDA (fy)
16.4×
EV/Sales (ttm)
7.3×
FCF yield (ttm)
8.10%
Buyback yield (realized, 1y)
3.05%
Shareholder yield (realized, 1y)
3.05%
Buyback yield (cash, ttm)
3.66%
Shareholder yield (cash, ttm)
3.66%

Vs own 10Y history

P/E
48th
P/OI
32nd
P/S
11th
P/B
95th
P/FCF
10th

Bar = where today’s multiple sits in HALO’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
-0.55%
5D
-6.81%
1M
-21.23%
3M
-6.83%
YTD
+42.60%
1Y
+36.01%
5Y
+160.65%
1D
-0.55%
5D
-6.81%
1M
-21.23%
3M
-6.83%
YTD
+42.60%
1Y
+36.01%
5Y
+160.65%

Fundamentals#

Revenue

5Y CAGR +39.2%10Y CAGR +26.3%YoY +39.2%
$1.8B TTM$493M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR +26.6%10Y n/mYoY +35.4%
$674.2M TTM$295M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +23.0%10Y n/mYoY +40.6%
$3.97 TTM$2.01 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +64.8%10Y n/mYoY +45.4%
$885.9M TTM$255.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $898.3M, capex −$12.4M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $258.3M, capex −$3M

Shares (diluted)

5Y −12.4%10Y −2.2%YoY +0.2%
122.2M TTM122.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR +19.7%10Y n/mYoY +41.0%
$485.4M TTM$247M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full HALO financials →

About Halozyme Therapeutics#

Data provided bySource: Twelve Data

Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.

San Diego, CA·423 employees·Biotechnology·halozyme.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding HALO#

21 of the 193 ETFs ChartRow carries live hold HALO. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
XBISPDR S&P Biotech ETF1.0%
IBBiShares Biotechnology ETF0.7%
VBKVanguard Small-Cap Growth ETF0.3%
IJHiShares Core S&P Mid-Cap ETF0.3%
MDYSPDR S&P MidCap 400 ETF Trust0.3%
IWPiShares Russell Mid-Cap Growth ETF0.3%
VHTVanguard Health Care ETF0.2%
VBVanguard Small-Cap ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%